NO20080754L - Rotavirusvaksine som induserer heterotypisk kryss-beskyttelse - Google Patents

Rotavirusvaksine som induserer heterotypisk kryss-beskyttelse

Info

Publication number
NO20080754L
NO20080754L NO20080754A NO20080754A NO20080754L NO 20080754 L NO20080754 L NO 20080754L NO 20080754 A NO20080754 A NO 20080754A NO 20080754 A NO20080754 A NO 20080754A NO 20080754 L NO20080754 L NO 20080754L
Authority
NO
Norway
Prior art keywords
induces
protection
rotavirus vaccine
heterotypic cross
heterotypic
Prior art date
Application number
NO20080754A
Other languages
English (en)
Norwegian (no)
Inventor
Brigitte Desiree Alberte Colau
Beatrice Arsene Virginie De Vos
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0516944A external-priority patent/GB0516944D0/en
Priority claimed from GB0521164A external-priority patent/GB0521164D0/en
Priority claimed from GB0608962A external-priority patent/GB0608962D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20080754L publication Critical patent/NO20080754L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20080754A 2005-08-17 2008-02-12 Rotavirusvaksine som induserer heterotypisk kryss-beskyttelse NO20080754L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0516944A GB0516944D0 (en) 2005-08-17 2005-08-17 Vaccine
GB0521164A GB0521164D0 (en) 2005-10-18 2005-10-18 Vaccine
GB0608962A GB0608962D0 (en) 2006-05-05 2006-05-05 Vaccine
PCT/EP2006/008094 WO2007020078A2 (fr) 2005-08-17 2006-08-15 Vaccin

Publications (1)

Publication Number Publication Date
NO20080754L true NO20080754L (no) 2008-05-15

Family

ID=37757924

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080754A NO20080754L (no) 2005-08-17 2008-02-12 Rotavirusvaksine som induserer heterotypisk kryss-beskyttelse

Country Status (25)

Country Link
US (1) US20090028828A1 (fr)
EP (2) EP2233153B1 (fr)
JP (1) JP5519934B2 (fr)
KR (1) KR20080036648A (fr)
AR (1) AR054916A1 (fr)
AU (1) AU2006281566B2 (fr)
BR (1) BRPI0615203A2 (fr)
CA (1) CA2619751C (fr)
CR (1) CR9759A (fr)
CY (1) CY1116135T1 (fr)
DK (1) DK2233153T3 (fr)
EA (1) EA014328B1 (fr)
ES (1) ES2534637T3 (fr)
HR (1) HRP20150310T1 (fr)
IL (1) IL189289A0 (fr)
MA (1) MA29700B1 (fr)
MX (1) MX2008002270A (fr)
NO (1) NO20080754L (fr)
PE (1) PE20070235A1 (fr)
PL (1) PL2233153T3 (fr)
PT (1) PT2233153E (fr)
SG (1) SG163571A1 (fr)
SI (1) SI2233153T1 (fr)
TW (1) TW200740457A (fr)
WO (1) WO2007020078A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0107510D0 (en) 2001-03-26 2001-05-16 Univ Bristol New elongase gene and a process for the production of -9-polyunsaturated fatty acids
WO2009042202A2 (fr) * 2007-09-25 2009-04-02 Aridis Pharmaceuticals Formulations pour la préservation de rotavirus
US9311112B2 (en) * 2009-03-16 2016-04-12 Apple Inc. Event recognition
BR112013027457A2 (pt) * 2011-04-28 2019-09-24 Int Medica Foundation preparação de vacina, e, métodos de fabricar uma preparação de vacina, e de vacinar um mamífero
CN110227152A (zh) * 2012-04-23 2019-09-13 巴拉特生物技术国际有限公司 轮状病毒疫苗组合物及其制备方法
US10548970B2 (en) 2015-10-05 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human rotavirus G9P[6] strain and use as a vaccine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008786A1 (fr) * 1990-11-16 1992-05-29 James N. Gamble Institute Of Medical Research Rotavirus humains, vaccins et procedes
DE122006000026I1 (de) * 1999-08-17 2006-10-12 Glaxosmithkline Biolog Sa Methoden um Rotavirusvarianten zu trennen und lebender attenuierter Rotavirus impfstoff
RU2368392C2 (ru) * 2003-09-02 2009-09-27 ГлаксоСмитКлайн Байолоджикалз с.а. Применение аттенуированного ротавирусного штамма серотипа g1 в изготовлении композиции для индукции иммунного ответа на ротавирусную инфекцию

Also Published As

Publication number Publication date
AU2006281566A1 (en) 2007-02-22
EA200800320A1 (ru) 2008-10-30
EP2233153B1 (fr) 2015-01-21
US20090028828A1 (en) 2009-01-29
PL2233153T3 (pl) 2015-06-30
CA2619751C (fr) 2016-07-05
EP2233153A1 (fr) 2010-09-29
MX2008002270A (es) 2008-03-27
BRPI0615203A2 (pt) 2011-05-10
KR20080036648A (ko) 2008-04-28
PT2233153E (pt) 2015-04-20
EA014328B1 (ru) 2010-10-29
IL189289A0 (en) 2008-06-05
EP1915173A2 (fr) 2008-04-30
AU2006281566B2 (en) 2011-09-01
JP5519934B2 (ja) 2014-06-11
AR054916A1 (es) 2007-07-25
HRP20150310T1 (hr) 2015-06-19
TW200740457A (en) 2007-11-01
PE20070235A1 (es) 2007-04-04
MA29700B1 (fr) 2008-08-01
WO2007020078A3 (fr) 2007-05-24
CR9759A (es) 2008-05-05
CA2619751A1 (fr) 2007-02-22
CY1116135T1 (el) 2017-02-08
JP2009504701A (ja) 2009-02-05
ES2534637T3 (es) 2015-04-27
SI2233153T1 (sl) 2015-05-29
WO2007020078A2 (fr) 2007-02-22
SG163571A1 (en) 2010-08-30
DK2233153T3 (da) 2015-04-27

Similar Documents

Publication Publication Date Title
NO20080754L (no) Rotavirusvaksine som induserer heterotypisk kryss-beskyttelse
JO3257B1 (ar) مركبات وتركيبات كمعدلات لفاعلية tlr
NO20074238L (no) Fiksert dosering av HER-antistoffer
WO2011027222A3 (fr) Compositions immunogènes comprenant des modulateurs de l'activité tlr
EA201301320A1 (ru) 4-арил-n-фенил-1,3,5-триазин-2-амины, которые содержат сульфоксиминную группу
TN2015000185A1 (en) 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
WO2006072888A3 (fr) Composition utile pour le traitement de l'atherosclerose
NO20060976L (no) Vaksine
MX2013012233A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas sustituidas.
NO20080951L (no) Farmasoytisk blanding for behandling av kardiovaskulaere lidelser
NO20080993L (no) Fremgangsmate for a forbedre arvakenhet
DE60011560D1 (de) Salmonella Impfstoff, der keinen Antikörper gegen Flagellin oder gegen Flagella induziert
IL187012A0 (en) Methods of using pnkp30, a member of the b7 family, to modulate the immune system
WO2010028072A3 (fr) Anticorps aviaires spécifiques du virus de la grippe et procédés technologiquement simples de fabrication et d'utilisation de ceux-ci
MA32305B1 (fr) Vaccin contre le virus vivant attenue inactive de la fievre catarrhale ovine
WO2007070678A3 (fr) Vaccin contre la rage
WO2012071521A3 (fr) Adjuvant
ATE519611T1 (de) Haushaltsgerät
MX2012002209A (es) Formulaciones de liberacion controlada de compuestos de anabaseina y usos de los mismos.
WO2006088997A3 (fr) Activites adjuvantes de b-pentameres d'enterotoxine lt-iia et lt-iib
TW200710224A (en) Attenuated avian infectious bronchitis virus vaccines
WO2009158409A3 (fr) Pimap39 modulant la réponse inflammatoire
CY1114309T1 (el) Εμβολιο ροταϊου
TH87301B (th) วัคซีน

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application